Agree with the comparison with PME in terms of shares issued and no debt and revenues which are all good parameters for investment IMO, especially in biotech and during a pandemic. Unfortunately for CUV , this years revenue will be on par with last year as they will not record USA sales yet I believe. Their cash build might maintain the dividend and their expenses will be up I imagine. Next year adding additional countries in Europe and Asia for EPP and USA sales for EPP alone will significantly lift the revenue. We should get progress on Vitiligo, OTC and other indications, which is why next year could be the transformative one all going well. Now should be a decent entry point for investors small or large before some additional milestones are reached. DYOR. Cheers
Shorts - general info, page-116
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.28 |
Change
-0.250(1.85%) |
Mkt cap ! $664.8M | |||
| Open | High | Low | Value | Volume |
| $13.55 | $13.62 | $13.25 | $1.157M | 86.45K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 227 | $13.28 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.42 | 228 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| CUV (ASX) Chart |